Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Lilly pulls back from Foghorn's synthetic lethality work as biotech sheds 40% of staff

Eli Lilly is walking away from Foghorn Therapeutics' "synthetic lethality" drug development, and the small biotech is reducing its headcount by 40% as a result of the culled collaboration. The duo is dropping a Phase ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

Qatar Hosts 2nd Uveitis Conference

The Second Qatar Uveitis Conference, organized by the Qatar Ophthalmology Society in collaboration with the Middle East Africa Uveitis Society (MEUS) and the Middle East Africa Council of…

More from Thursday 1 October →